{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:00:10Z","timestamp":1784595610845,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s11886-017-0836-z","type":"journal-article","created":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T22:01:11Z","timestamp":1489528871000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bioresorbable Scaffolds for Coronary Stenosis: When and How Based Upon Current Studies"],"prefix":"10.1007","volume":"19","author":[{"given":"Alexandre","family":"Abizaid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"J.","family":"Ribamar Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,15]]},"reference":[{"issue":"7","key":"836_CR1","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.jacc.2015.11.060","volume":"67","author":"PW Serruys","year":"2016","unstructured":"Serruys PW, Ormiston J, van Geuns RJ, de Bruyne B, Dudek D, Christiansen E, et al. A polylactide bioresorbable scaffold eluting everolimus for treatment of coronary stenosis: 5-year follow-up. J Am Coll Cardiol. 2016;67(7):766\u201376.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"836_CR2","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.4244\/EIJV10I12A243","volume":"10","author":"A Abizaid","year":"2015","unstructured":"Abizaid A, Ribamar Costa Jr J, Bartorelli AL, Whitbourn R, van Geuns RJ, Chevalier B, et al. The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention. 2015;10(12):1396\u2013401.","journal-title":"EuroIntervention"},{"issue":"10","key":"836_CR3","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.4244\/EIJY14M07_11","volume":"10","author":"D Capodanno","year":"2015","unstructured":"\u2022 Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015;10(10):1144\u201353. This was the first \u201creal-world\u201d study to point to the possibility of higher thrombosis rate following the use of BRS.","journal-title":"EuroIntervention"},{"issue":"10025","key":"836_CR4","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S0140-6736(15)01039-9","volume":"387","author":"GW Stone","year":"2016","unstructured":"Stone GW, Gao R, Kimura T, Kereiakes DJ, Ellis SG, Onuma Y, et al. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016;387(10025):1277\u201389.","journal-title":"Lancet"},{"issue":"21","key":"836_CR5","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1016\/j.jacc.2015.10.002","volume":"66","author":"S Windecker","year":"2015","unstructured":"\u2022 Windecker S, Koskinas KC, Siontis GC. Bioresorbable scaffolds versus metallic drug-eluting stents: are we getting any closer to a paradigm shift? J Am Coll Cardiol. 2015;66(21):2310\u20134. This editorial addresses most of the issues related with ABSORB BRS acute\/subacute thrombosis and present a meta-analysis of the main randomized studies published at the time.","journal-title":"J Am Coll Cardiol"},{"issue":"10059","key":"836_CR6","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/S0140-6736(16)32050-5","volume":"388","author":"PW Serruys","year":"2016","unstructured":"Serruys PW, Chevalier B, Sotomi Y, Cequier A, Carri\u00e9 D, Piek JJ, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016;388(10059):2479\u201391.","journal-title":"Lancet"},{"issue":"12","key":"836_CR7","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/j.jcin.2014.06.016","volume":"7","author":"Y Onuma","year":"2014","unstructured":"Onuma Y, Serruys PW, Muramatsu T, Nakatani S, van Geuns RJ, de Bruyne B, et al. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2014;7(12):1400\u201311.","journal-title":"JACC Cardiovasc Interv"},{"key":"836_CR8","doi-asserted-by":"crossref","unstructured":"Sotomi Y, Suwannasom P, Serruys PW, Onuma Y. Possible mechanical causes of scaffold thrombosis: insights from case reports with intracoronary Imaging. EuroIntervention. 2017;20;12(14):1747\u20131756.","DOI":"10.4244\/EIJ-D-16-00471"},{"issue":"17","key":"836_CR9","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.jacc.2015.08.853","volume":"66","author":"L R\u00e4ber","year":"2015","unstructured":"R\u00e4ber L, Brugaletta S, Yamaji K, O'Sullivan CJ, Otsuki S, Koppara T, et al. Very late scaffold thrombosis: intracoronary imaging and histopathological and spectroscopic findings. J Am Coll Cardiol. 2015;66(17):1901\u201314.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"836_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4244\/EIJY15M02_03","volume":"11","author":"JA Ormiston","year":"2015","unstructured":"Ormiston JA, Webber B, Ubod B, Darremont O, Webster MW. An independent bench comparison of two bioresorbable drug-eluting coronary scaffolds (Absorb and DESolve) with a durable metallic drug-eluting stent (ML8\/Xpedition). EuroIntervention. 2015;11(1):60\u20137.","journal-title":"EuroIntervention"},{"issue":"20","key":"836_CR11","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1056\/NEJMoa1509038","volume":"373","author":"SG Ellis","year":"2015","unstructured":"\u2022\u2022 Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015;373(20):1905\u201315. This study was the first to randomize patients treated with BRS versus DES based on clinical outcomes.","journal-title":"N Engl J Med"},{"key":"836_CR12","doi-asserted-by":"crossref","unstructured":"Andrade JD, Hlady V. Plasma protein adsorbtion: the big twelve. In: Leonard EF, Turitto VT, Vroman I, eds. Blood in contact with natural and artificial surfaces. Ann N Y Acad Sci. 1987;516:158\u201372.","DOI":"10.1111\/j.1749-6632.1987.tb33038.x"},{"key":"836_CR13","unstructured":"Wang K. Biocompatibilisation of coronary artery stents. Acta Biomed Lovan. 1997."},{"key":"836_CR14","doi-asserted-by":"crossref","unstructured":"Steinemann SG. Metal implants and surface reactions. Injury. 1996;27 Suppl 3:SC16\u201322.","DOI":"10.1016\/0020-1383(96)89027-9"},{"key":"836_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1540-8183.2000.tb00286.x","volume":"13","author":"I Scheerder de","year":"2000","unstructured":"de Scheerder I, Sohier J, Wang K. Metallic surface treatment using electrochemical polishing decreases thrombogenicity and neointimal hyperplasia of coronary stents. J Int Cardiol. 2000;13:179.","journal-title":"J Int Cardiol"},{"issue":"18S","key":"836_CR16","doi-asserted-by":"publisher","first-page":"B12","DOI":"10.1016\/j.jacc.2016.09.050","volume":"68","author":"J Simonsen","year":"2016","unstructured":"Simonsen J, Holck E, Carri\u00e9 D, Frey N, Lutz M, Weber-Albers J, et al. Performance and healing patterns after implantation of a novel sirolimus eluting bioresorbable scaffold. Six-month follow-up by optical coherence tomography in the FANTOM II study. J Am Coll Cardiol. 2016;68(18S):B12.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"836_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jcin.2012.09.017","volume":"6","author":"HG Bezerra","year":"2013","unstructured":"Bezerra HG, Attizzani GF, Sirbu V, Musumeci G, Lortkipanidze N, Fujino Y, et al. Optical coherence tomography versus intravascular ultrasound to evaluate coronary artery disease and percutaneous coronary intervention. JACC Cardiovasc Interv. 2013;6(3):228\u201336.","journal-title":"JACC Cardiovasc Interv"},{"issue":"10","key":"836_CR18","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.jcmg.2013.04.014","volume":"6","author":"T Kubo","year":"2013","unstructured":"Kubo T, Akasaka T, Shite J, Suzuki T, Uemura S, Yu B, et al. OCT compared with IVUS in a coronary lesion assessment: the OPUS-CLASS study. JACC Cardiovasc Imaging. 2013;6(10):1095\u2013104.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"7","key":"836_CR19","doi-asserted-by":"publisher","first-page":"875","DOI":"10.4244\/EIJV6I7A149","volume":"6","author":"S Tahara","year":"2011","unstructured":"Tahara S, Bezerra HG, Baibars M, Kyono H, Wang W, Pokras S, et al. In vitro validation of new Fourier-domain optical coherence tomography. EuroIntervention. 2011;6(7):875\u201382.","journal-title":"EuroIntervention"},{"key":"836_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ijcard.2014.11.168","volume":"180","author":"B Cortese","year":"2015","unstructured":"Cortese B, Valgimigli M. Current know how on the absorb BVS technology: an experts\u2019 survey. Int J Cardiol. 2015;180:203\u20135.","journal-title":"Int J Cardiol"},{"key":"836_CR21","doi-asserted-by":"crossref","unstructured":"Tamburino C, Latib A, van Geuns RJ, Sabate M, Mehilli J, Gori T, et al. Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. EuroIntervention. 2015;11(1):45\u201352.","DOI":"10.4244\/EIJY15M01_05"},{"issue":"2","key":"836_CR22","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jbiomech.2013.10.048","volume":"47","author":"F Rikhtegar","year":"2014","unstructured":"Rikhtegar F, Wyss C, Stok KS, Poulikakos D, M\u00fcller R, Kurtcuoglu V. Hemodynamics in coronary arteries with overlapping stents. J Biomech. 2014;47(2):505\u201311.","journal-title":"J Biomech"},{"issue":"3","key":"836_CR23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jcin.2012.10.013","volume":"6","author":"T Muramatsu","year":"2013","unstructured":"Muramatsu T, Onuma Y, Garc\u00eda-Garc\u00eda HM, ABSORB EXTEND Investigators, et al. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials. JACC Cardiovasc Interv. 2013;6(3):247\u201357.","journal-title":"JACC Cardiovasc Interv"},{"issue":"8","key":"836_CR24","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jcin.2015.06.001","volume":"8","author":"Y Ishibashi","year":"2015","unstructured":"Ishibashi Y, Muramatsu T, Nakatani S, Sotomi Y, Suwannasom P, Grundeken MJ, et al. Incidence and potential mechanism(s) of post-procedural rise of cardiac biomarker in patients with coronary artery narrowing after implantation of an everolimus-eluting bioresorbable vascular scaffold or everolimus-eluting metallic stent. JACC Cardiovasc Interv. 2015;8(8):1053\u201363.","journal-title":"JACC Cardiovasc Interv"},{"issue":"5","key":"836_CR25","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jcin.2012.12.131","volume":"6","author":"V Farooq","year":"2013","unstructured":"Farooq V, Serruys PW, Heo JH, et al. Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice. JACC Cardiovasc Interv. 2013;6(5):523\u201332.","journal-title":"JACC Cardiovasc Interv"},{"key":"836_CR26","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jacc.2015.12.019","volume":"67","author":"S Puricel","year":"2016","unstructured":"Puricel S, Cuculi F, Weissner M, Schmermund A, Jamshidi P, Nyffenegger T, et al. Bioresorbable coronary scaffold thrombosis: multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors. J Am Coll Cardiol. 2016;67:921\u201331.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"836_CR27","doi-asserted-by":"publisher","first-page":"e550","DOI":"10.4244\/EIJY15M09_10","volume":"12","author":"T Gori","year":"2016","unstructured":"Gori T, Wiebe J, Capodanno D, Latib A, Lesiak M, Pyxaras SA, et al. Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry. EuroIntervention. 2016;12(5):e550\u20136.","journal-title":"EuroIntervention"},{"issue":"11","key":"836_CR28","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.4244\/EIJV7I11A206","volume":"7","author":"Y Huo","year":"2012","unstructured":"Huo Y, Finet G, Lef\u00e8vre T, Louvard Y, Moussa I, Kassab GS. Optimal diameter of diseased bifurcation segment: a practical rule for percutaneous coronary intervention. EuroIntervention. 2012;7(11):1310\u20136.","journal-title":"EuroIntervention"},{"key":"836_CR29","doi-asserted-by":"crossref","unstructured":"Bennett J, Vanhaverbeke M, Vanden Driessche N, Adriaenssens T, Hiltrop N, Desmet W, et al. Absorb bioresorbable vascular scaffold in complex coronary bifurcation interventions: insights from an in vivo multimodality imaging study. Circ Cardiovasc Interv. 2016;9(8).","DOI":"10.1161\/CIRCINTERVENTIONS.116.003849"},{"issue":"13","key":"836_CR30","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jcin.2016.04.021","volume":"9","author":"F Derimay","year":"2016","unstructured":"Derimay F, Souteyrand G, Motreff P, Guerin P, Pilet P, Ohayon J, et al. Sequential proximal optimizing technique in provisional bifurcation stenting with everolimus-eluting bioresorbable vascular scaffold: fractal coronary bifurcation bench for comparative test between Absorb and XIENCE Xpedition. JACC Cardiovasc Interv. 2016;9(13):1397\u2013406.","journal-title":"JACC Cardiovasc Interv"},{"issue":"6","key":"836_CR31","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/ccd.26579","volume":"88","author":"A Tanaka","year":"2016","unstructured":"Tanaka A, Latib A, Kawamoto H, Jabbour RJ, Mangieri A, Pagnesi M, et al. Clinical outcomes following bifurcation double-stenting with bioresorbable scaffolds. Catheter Cardiovasc Interv. 2016;88(6):854\u201362.","journal-title":"Catheter Cardiovasc Interv"},{"key":"836_CR32","doi-asserted-by":"crossref","unstructured":"Naganuma T, Colombo A, Lesiak M, Capodanno D, Gori T, Nef H, et al. Bioresorbable vascular scaffold use for coronary bifurcation lesions: A substudy from GHOST EU registry. Catheter Cardiovasc Interv. 2017;89(1):47\u201356.","DOI":"10.1002\/ccd.26634"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-017-0836-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-017-0836-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-017-0836-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T15:48:41Z","timestamp":1581954521000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-017-0836-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["836"],"URL":"https:\/\/doi.org\/10.1007\/s11886-017-0836-z","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"15 March 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Alexandre Abizaid reports grants and personal fees from Abbott Vascular, grants and personal fees from Elixir Medical, and personal fees from Reva Medical. J. Ribamar Costa Jr reports his Institution (Dante Pazzaenese) has received research grants from Abbott Vascular, Elixir Medical, and Reva Medical.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"27"}}